AAV2.5T Serotype

Chimeric serotype combining AAV2 and AAV5 capsid sequences for enhanced muscle transduction with improved tissue distribution.

Length: 1 bp

Tropism: Skeletal muscle, cardiac muscle

Characteristics

Hybrid capsid structure combining AAV2 and AAV5 sequences. Enhanced muscle transduction efficiency versus parental serotypes. Improved intramuscular spread. Reduced immunogenicity profile.

Applications: Duchenne muscular dystrophy gene therapy. Limb-girdle muscular dystrophies. Cardiac gene therapy applications.

References

  1. Bowles et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther - Bowles 2012 AAV2.5T